April 2, 2025 • 34 mins
Thanks for tuning in to this episode of Follow The Brand! We hope you enjoyed learning about the latest marketing trends and strategies in Personal Branding, Business and Career Development, Financial Empowerment, Technology Innovation, and Executive Presence. To keep up with the latest insights and updates from us, be sure to follow us at 5starbdm.com. See you next time on Follow The Brand!
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:02):
Welcome everybody to the Follow Brand Podcast.
This is your host, grantMcGaugh.
We're going to keep it righthere in South Florida, in
Broward County, at MemorialHealthcare System.
Kyle Roebuck here Now.
I ran into this gentlemanthrough the HIMSS organization.
I'm a big HIMSS fan, programchair for HIMSS for a very long
(00:23):
time, and I found his story tobe intriguing and I've done a
lot of work in the cancer world.
And we got to talking.
He said hey, grant, I'm doing alot in genetics, I'm doing
precision medicine, I'm doingthings that help cancer
treatment get better, and I wantto tell my story.
And I went well, let's hearyour story then, kyle, let's
(00:47):
talk about this.
First, introduce yourself.
Speaker 2 (00:51):
Hi everyone.
My name is Kyle Roebuck.
I am a molecular pathologytechnologist with Memorial
Healthcare System and I got mystart in research, interestingly
enough, in marine biology.
So I tell people that I'm amarine biologist turned health
care professional.
So that's the short story andthe long story could be for
(01:12):
another day.
Speaker 1 (01:15):
Well, you are a Florida.
You're Florida born, I wouldsay.
I mean literally born in thesame system in which you work
with.
Now, was that planned?
Tell us a little bit about yourbackground.
Speaker 2 (01:28):
By no means was it planned.
On a rainy day in August in1991, I was born at Memorial
Regional Hospital.
Back then it was calledMemorial Hospital, so I'm a
South Florida native through andthrough, grew up in Pembroke
Pines, went to Florida StateUniversity in Tallahassee and
(01:54):
then from there I went and didmy master's, my graduate
research at Nova SoutheasternUniversity, which another full
circle moment is.
Now I'm also teaching there asan adjunct professor.
So you can say that full circlemoments have pervaded my life
through and through.
So I'm very excited about thosetwo.
Speaker 1 (02:09):
I see you're a professor now at NOVA, you're
doing some work at Miami Collegeand obviously you do a lot of
work.
I mean, what is driving yourpassion in this world?
Most people you just said it isrolled off your tongue when
you're talking about a medical,biological pathology.
I mean that's a lot.
That's a lot of letters there.
Tell us exactly what that is.
Speaker 2 (02:30):
Yeah.
So what we do nowadays inprecision medicine and
specifically in oncology, we'removing away from the typical
naming cancers and naming tumorsby the site of origin and we're
moving towards identifying themby mutational profiles and what
mutations are in that patient'stumor and finding, finding
(02:53):
targetable treatments, precisiontreatments that are actually
going after those, thosemutations themselves, instead of
just a broad spectrumchemotherapy that you've been
getting for, you know, decadesfor now, you know up until now.
So that's an interesting partof the field and how we're
developing new therapies, youknow over time, and we're also
(03:14):
targeting specific mutations inthe patient's tumor instead of
just treating everyone as a onesize fits all type of approach.
Speaker 1 (03:21):
I think that's important.
And what you just said as faras therapies, medications, I
mean just having cancer itselfand telling somebody they have
cancer is tough and then if youhave more of a generic approach,
you really don't know how thatmedication or that therapy or
that treatment is going tobehave.
You know for that particularindividual, so kind of trial and
(03:44):
error.
So when I hear what you'resaying you were going more of a
precise treatment path, thatmeans you're honing in and
taking out all the unknowns,trying to get into a known
element and try to get to abetter result.
Have you seen that to be thecase now that you're in this
field and you're seeing the endresults of a lot of these cases?
Speaker 2 (04:07):
Yeah, I mean you could have two different tumors
that are from the same site oforigin, aka the lung, the brain,
pancreas but the mutationalprofiles could be completely
different.
And so, in order to have thatpersonalized approach, you have
to do the biomarker testing andonce you have those biomarkers
(04:28):
profiled, you can find whicheligible therapies are available
for that patient.
And so it really is a highlypersonalized approach.
That is, it's producing sideeffects that you get with
traditional chemotherapies andeventually being more effective
than those therapies.
Speaker 1 (04:48):
This is important.
Now, when you say biomarkers,are you talking about the
individual's biomarker or isthat or something specific in
the patient that is indicativeof?
Speaker 2 (04:58):
disease or of progression of disease, things
along those lines.
But specifically in oncology wetalk about biomarkers, as what
are the drivers of tumor genesisor what's deriving the
(05:21):
formation of that tumor?
And those are the types ofmutations that you're trying to
target and trying to investigateto find out what would be the
most efficacious andadvantageous treatment to
basically combat thattumorigenesis or the formation
of that tumor.
And I'm talking specificallyfor solid tumors in cancer.
(05:42):
Generically speaking, tumors orcancer is divided up into two
groups.
The solid tumors in cancer.
Generically speaking, tumors orcancer is divided up into two
groups the solid tumors and theblood cancers, which are the
leukemias, the lymphomas, themyelomas.
Those are also targetable, butthat's a different realm in
terms of biomedical research andand testing and that sort.
Speaker 1 (06:04):
As a.
You're a pathologist.
I want to help my audienceunderstand.
You know there's a.
You know the cancer doctor andan oncologist.
You are the pathologist.
How do you work together?
Speaker 2 (06:20):
So I'm not a pathologist.
A pathologist is an MD, is atrained doctor.
So I'm a molecular pathologytechnologist and what I do is I
perform the testing.
I perform the testing from thetissue all the way up until
there's data that is informativefor the oncologist to use in
guiding their treatment, theirtreatment regimen.
(06:41):
So we work intimately with thepathologists, who in turn work
with the oncologists, which arethe actual treating physicians
that are dealing with patientsday in and day out.
So that's the main distinctionthere.
Speaker 1 (06:56):
That's a major distinction.
So we're like, when you go inand I've seen this happen you go
in, you get a biopsy, which isa piece of tissue, right, they
take that biopsy and then theytake it through different
testing.
So when they take it throughdifferent testing, is that your
world?
You're actually looking at thattissue and trying to figure out
what's going on.
Speaker 2 (07:15):
That's exactly right.
So normally a person has abiopsy or a surgery and a piece
of tissue is taken out of them,and traditionally it's fixed in
a chemical called formalin,which stabilizes it, what we
call histologically, which is itpreserves the molecular
structure of all of the internalcomponents of that tissue.
(07:36):
And then afterwards, after it'sfixed in that chemical, it's
embedded in what's calledparaffin, paraffin wax, and that
combination of the formalinfixation and the paraffin
embedding is what we call.
It is called FFPE.
That's what the FFPE stands forand that's traditionally what's
(07:56):
used nowadays to do thediagnostics.
And so that's essentially yourstarting tissue that you begin
the process of discovering thesebiomarkers.
Speaker 1 (08:07):
This is interesting.
Now I want to ask becauseyou're at this juncture
intersection of health care andtechnology because I met you at
HIMSS HIMSS is the HealthInformatics Systems Society.
Now I'm curious as to howyou're applying technology.
Are you're applying, you know,known AI algorithms?
(08:30):
Are you doing you know scanningimaging?
Tell us how you utilizetechnology in your trade.
Speaker 2 (08:35):
So one particular method to discover these
biomarkers is callednext-generation sequencing and
that's a method to scanessentially a vast majority of
biomarkers within a tumor.
In this, if we give thisexample in oncology, to find all
of the specific nucleotidebases that are in a sequence
(08:56):
that make up that tumor and Tofind those mutations, we have to
align those sequences to what'scalled a reference genome,
which is a grouping of humangenomes that have been kind of
the gold standard of what we useas comparison to basically call
mutations in that patient'stumor.
(09:17):
And so there's a lot oftechnological requirements to do
that, a lot of algorithms, alot of information technology
type solutions that are neededto do that computational
(09:38):
generation of that data.
So that's really the demand forinformation technology and use
(10:04):
of algorithms and importing thatdata into patient charts and
into EHRs.
Speaker 1 (10:10):
This is important information.
So you're taking massiveamounts of data, of information
that you have in variousdatabases to, I guess,
cross-reference, trying to getto a particular understanding of
what you have in front of youas far as this tissue, whatever
its molecular regeneration, isdoing to kind of isolate the
(10:34):
cancer and what it is.
A lot of people and I wouldlike you to tell our audience
what exactly is cancer.
I mean, they understand it's adifferent cellular generation,
but it's a type of disease thatis different from other things
(10:55):
that are happening that causesyou to do this kind of work.
Tell us more about what canceris and how, when you have all
this data and this information,what you're able to then
instruct the oncologist orpathologist on.
Speaker 2 (11:13):
So when you break it down into the simplest terms,
cancer is really justuncontrolled cellular division.
So normally in our normal cellsthey go through a series of
checkpoints as they get ready todivide and they grow and they
divide again under a processcalled mitosis.
In cancerous cells theinstructions to go through those
(11:38):
processes are a little bitdamaged and so the cells don't
normally go through or don't gothrough those processes checked
in a series of checkpoints.
They're bypassing thosecheckpoints, they're going
faster, they're multiplyingunregulated and unchecked and
that's what causes the eventualformation of a tumor, which is
(12:00):
just a bunch of cells growing inone area that form an actual
mass.
So that's really what cancer is.
It's uncontrolled cell divisionand cells that kind of have
gone rogue compared to the cellsthat are essentially behaving
normally.
Speaker 1 (12:16):
This is interesting, but we don't know what causes
that to happen.
What causes that mutation?
Is that what you say?
It's in the instructions at thecellular level.
Do we have information aboutthat?
One group is called oncogenesand then another group is called
tumor suppressor genes.
Speaker 2 (12:31):
So tumor suppressor genes are there and their main
responsibility is to inhibituncontrolled cell division.
And so in those tumorsuppressor genes, if those are
(12:53):
mutated, they are not doingtheir job to suppress tumor
formation.
And conversely, in oncogenes,those are genes that induce
cellular proliferation andcellular division.
So by the absence of mutationsin oncogenes and by the presence
(13:15):
of mutations in tumorsuppressor genes, the
combination of those or themworking by themselves, will lead
to the production of a tumor.
Speaker 1 (13:27):
And then do you take this information.
Once you've done your work andyou've done your research, then
you sit down with the oncologistor the pathologist.
This is the work that I'mpresenting to you.
Is that what happens, or is itdifferent?
Speaker 2 (13:43):
Yeah, so that data?
Is that what happens or is itdifferent?
Yeah, so that's that data is isprovided to a pathologist and
that data is analyzed by thatpathologist and they determine
what is relevant for that tumortype and so that once that data
report is completed, that getssent to the oncologist and then
that oncologist digests thatinformation with all the other
(14:05):
information that they're gettingand decides on a treatment
regimen from that data.
Speaker 1 (14:10):
This is interesting.
Now you said you're a professor, and you're a professor at two
institutions, at NOVA and alsoMiami Dade College.
Are you teaching this type ofinformation and technology and
and or is it something totallydifferent?
Speaker 2 (14:26):
I'm teaching this in a much more rudimentary sense,
um undergraduate and graduatelevel um, not specifically
cancer related, but um more of aa generic genomics and genome
biology sense Um, but the theprinciples and the ideas and the
concepts are similar.
It's just on a much moreundergraduate and graduate level
(14:50):
, not as high level as what I'mspeaking about now and what I do
on a day-to-day basis in thelab.
Speaker 1 (14:58):
Yes, exactly Now, genomics, genomics.
There's different distinctions,right as we get into now
genomics and genomics genomics.
There's different distinctions,right as we get into now
genomics and genomics is a wholenother animal because it
affects so many different things.
And how do you look at genomics?
And if you had to give adefinition like hey, professor
roebuck, what is genomics?
Speaker 2 (15:21):
well, it's really the study of a genome, of an
organism in its broadest sense,and that's where I came from
research actually on marineinvertebrates and organisms in
the ocean that are reallyrudimentary and preliminary
study organisms for things thatare happening in cancer and a
(15:47):
lot of, for example, a lot ofcancer drugs are isolates from
sponges or are derivatives ofsecondary metabolites of sponges
that are actually found in theocean.
So that was my my first workabout a decade ago, but then
it's led me here to to do thework on actual patients that
have been diagnosed with cancerand has offered me the ability
(16:08):
to give back so much more of myeducation and my background to
help human health in a muchgreater sense.
So that's kind of the journeyI've a little bit longer of a,
of an explanation of the journeyI've been on.
Speaker 1 (16:24):
No, this is interesting.
You just told me that you arecuring cancer from the ocean and
beings in the ocean.
Is that what I heard?
Speaker 2 (16:35):
Yes, yeah.
So most people, a lot of people, are surprised at the fact that
a lot of the cancer drugs, avast majority of the cancer
drugs, have been modeled or havebeen derived or have been
synthetically made based off ofderivatives of sponges and other
organisms in the ocean, andthat's, that's another, just
(16:56):
another reason why we need toprotect the oceans, but that's
another, another talk in and ofitself, another talk in and of
itself.
But, yeah, that's that's again.
That's that's part of my storyand how I've I've moved as a
move from a marine biologistturned to healthcare
professional.
Speaker 1 (17:13):
Now, as you go through that story, I want you
to think about this you know,starting out and getting your
undergrad and then going throughgrad school, now being out in
the world actually doing thiswork, teaching this work, what
is the most interesting thing?
That just really kind of mindblows you about the work that
(17:34):
you do?
Speaker 2 (17:36):
Really, I think it's just the fast-paced nature of
how many things are developingon a day-to-day basis, what
things are being discovered on aday-to-day basis, what things
are being discovered on aday-to-day basis.
That's what, that's what got meso interested in science in the
first place.
It's just how much technologyis changing, how much we're
finding out day-to-day newdevelopments, new, new
discoveries, and that's, to me,is the most exciting part of
(18:00):
science in general.
And then, even more so, biology, and if you get really granular
in terms of what I do today iscancer biology.
Speaker 1 (18:11):
You've intrigued me.
I mean I've learned somethingbig.
For me it's a big thing thatwe're getting cancer treatments
from microorganisms or organismsin the ocean that we find that
then can then combat thismutation and really your body is
kind of fighting itself is whatI'm hearing in cancer, and I've
(18:35):
heard that there's certainother causes.
People are looking at dietcould be a cause.
There's some external forcesthat could be getting in there
and creating these types ofthings.
Or maybe your immune system isjust not as strong to withstand
some of these activities thatare going on at the cellular
level.
I mean, this sounds to be tosolve for this problem that's
(19:09):
occurring within a person.
I find that fascinating.
Speaker 2 (19:15):
It is.
It really is fascinating aboutall of the biomedical research
that's going into cancer itselfand finding information about
all the factors that could gointo the production of a tumor
inside your body and what, what.
It also makes you appreciatehow many things have to go right
, because in the, in an instant,things can go wrong, and so it
(19:38):
really it.
It makes me, it reminds me, howmany things have to go right,
and and and.
It gives me a much greaterappreciation for science, for
biology, for what I've done inthe past, what I'm doing now,
and just the benefits that arebeing imparted onto human health
(20:00):
.
Speaker 1 (20:01):
Now you've been invited on many stages.
People want to hear from youand talk to you about your
research right and what you'redoing.
Why are you, kyle Roebuck,being asked to come onto these
stages and what exactly is thekind of knowledge that you're
imparting?
Speaker 2 (20:20):
I think it's my diverse background, the
different things that I've beenlucky enough to be a part of and
to experience and really learn.
I think that multidisciplinaryand that diverse background is a
huge attribute for myself andmy career and it's given me
(20:41):
perspective and it's allowed meto learn things that most other
people haven't learned, that aremaybe in the clinic and in
healthcare, because I've comefrom research and now I'm in the
clinic and I'm doing clinicalstuff.
So I think that that diversityand that multidisciplinary
background is is very beneficialfor my, for myself and my
(21:02):
career, and I think it's alsobecome beneficial to you know my
current role and at at you knowmy current day job, and then
also for my, my professor.
You know my, my, my, myteaching responsibilities as
well.
Speaker 1 (21:18):
I tell you you've sold me on your credibility and
your authenticity when you marrythose teams together that you
know you, when you say somethingin this realm it rings true.
People like huh, you know ifkyle?
I'm sure kyle knows what he'stalking about because he's done
the research.
You know you always like thathe's not going to just throw
(21:39):
some ideas out there.
Like you know, I've done theresearch, I've seen the trials.
I know what happens on thebefore, the during and the after
.
I want to ask you this In fiveyears, let's say we fast forward
five years it's the year 2030.
What is Kyle Roebuck doing?
Speaker 2 (22:02):
I think that's the exciting part is the not knowing
, because so much is changingand so much has changed in my
life in the last three and ahalf four years and I think that
that the industry that I'mworking in is is is
exponentially changing, dayafter day and year after year,
so I don't really know where mycareer is going to take me.
(22:23):
I'm just excited for the ride.
Speaker 1 (22:26):
Well, let's take that for a ride just a little bit
further.
I want to unpack that just alittle bit.
I want to ask you this If youcould make a difference in what
you're doing in cancer treatment, money wasn't an object.
Nothing was an obstacle in yourway.
Let's just say, what would thatbe?
Speaker 2 (22:53):
your way.
Let's just say, what would thatbe?
I think, in the most basicsense, I would just like to get
cancer patients treated fasterand whether it be you know
diagnosed faster.
We talk a lot about screeninginitiatives nowadays.
We talk about education, wetalk about advocacy.
All of those things will helpbring diagnostics of cancer up
(23:15):
to the forefront and expeditethose, so that you are not
diagnosing people in late stagecancer, You're not diagnosing
metastatic disease.
You can help save more livesbecause you're getting those
people in the appropriatetreatments faster and that, I
think, is is the most ambitiousand and and worthwhile goal that
(23:40):
we can, that we can go forright now and we can strive to,
to, to, you know, work towards.
Speaker 1 (23:46):
I like that.
I think that's a big, that'snot only a nice goal, that's
something we can change.
The awareness factor, like yousaid, screening, making sure
that we're informing ourpopulation, our communities.
You've got to get in thereearly and get these kinds of
(24:06):
screenings to take place.
You know, and so answer me this, because something you know you
get a yearly physical right,but cancer screen you don't
normally get screened for cancer.
How can we help with that?
Speaker 2 (24:22):
I think there's.
It depends on the specialty,the medical specialty, I think.
You know.
At my last physical I was asked, you know, when were you at
your dentist the last time?
When were you at adermatologist the last time?
Because of the prevalence,especially in South Florida, of
skin cancer and how things arego unnoticed or you don't.
(24:42):
You know, things are out ofsight, out of mind and, and you
know, going to those thoseprimary visit, the primary
doctor visits that are at, thosedoctors are asking you, are you
going to those specialties?
Are you having those regularcheckups?
Are you doing as much as youcan to preempt any of this?
you know, this possiblediagnosis of of cancer, whether
(25:05):
it be you know an optometrist,or you know a urologist or a you
know a gastroenterologist.
Are you having those symptoms?
Are you?
Are you, are you being providedthat education so that, when
you do potentially have thosesymptoms, are you aware how to
go about it?
What do you need to do and thatI think is really powerful, and
(25:28):
how?
How you know, I thinkhealthcare is changing, and and
to have to enable patients totake ownership of their own
healthcare and to be their bestadvocate and understand that you
know, your intuition may be theright call.
Even though you might bedismissed by by a doctor, you
know your body and you know yourhealth better than anyone else
(25:50):
does, and so enabling andempowering patients to take
ownership of their health care,I think, is another great
initiative that's going on rightnow.
Speaker 1 (26:00):
I think you're right.
I talked to a doctor lastsummer and he was a cancer
doctor, oncologist in themelanoma world, and we're
talking about melanoma and Ididn't know.
He said do you realize, likemost people, when they actually
get, uh, melanoma or you knowthe cancer, they get it when
(26:22):
they're a child, right in thesun, but it doesn't develop, you
know, until usually much later,so you're already exposed to it
.
You were you.
You don't even realize youcould have been five, six years
old, because I guess somethinglike your skin is not as strong
to withstand some of the sun'srays and that type of thing.
(26:44):
I didn't know that, you know.
I just had no idea that goingto the beach you're five, six
years old and if you didn't havethe right sunblocks on, you can
be developing cancer and youwouldn't even realize you have
it two years later.
Speaker 2 (27:00):
Right, and it could be.
Children don't like to listento their parents and if they to
being told, being told, go puton the sunblock and they don't
put it on well enough or theydon't do it at all, you know
that that could be another,another issue, um, but yeah,
it's a lot of a lot.
There's a lot of, um, potentialcauses of, of, of cancer, and I
think, especially in SouthFlorida, being the, you know,
(27:23):
the sunshine state and being ahotbed for no pun intended for
the sun, you know melanoma is aparticularly problematic, you
know, skin cancer type in theregion.
Speaker 1 (27:39):
So let me ask you this when it comes to genetics,
do you find that certaindemographics of people are prone
to different types of cancerswhether it's their ethnicity,
their race, maybe even theirlocation than others?
Speaker 2 (27:55):
I think there's a lot of research, especially now,
going into social determinantsof health and effects of race
and ethnicity and whetherthey're genetically predisposed
to different types of cancerbased on which demographic you
belong to.
But I think that's still anongoing area of research and it
(28:16):
needs a little bit moreinvestigation.
Speaker 1 (28:18):
Do you think?
Is it genetic?
Let's say your parent hadcancer?
Is the likelihood you hadcancer, or a grandparent, or is
it something different?
Speaker 2 (28:25):
or is it something different?
Yeah, I think there'sdefinitely anecdotal stories of
you know parents andgrandparents and family lineage
of whether it's breast cancer,colon cancer.
You know pancreatic prostate,what have you.
(28:46):
There's definitely anecdotalevidence that shows that there's
potentially a genetic linkthere.
And you know, we heard maybeabout a decade ago or 15 years
ago, you know, testing for theBRCA gene was a very popular
thing and so that's.
You know, there's some evidencethat there is a genetic
predisposition for developingcancer.
(29:07):
But I think it needs a lot moreinvestigational research to
really hammer down and nail downthat true, definite link.
Speaker 1 (29:17):
Well, I want to give you some research grants and
some more funding.
That sounds good.
Any way I can, because it'simportant, right.
It is Any way I can becauseit's important, right it is To
understand that I mean, whowould have known?
Hey, let's go out to the oceanand look at some sponges and do
some, you know, some research onthem and see what they have
(29:41):
going on with them, and then wecan actually help a human being
to cure cancer.
To me that's such a leap, it'salmost miraculous.
Like how would that even occur?
But you're telling me thatthere's so many things in the
natural world that potentiallycan help in our human journey
(30:01):
that we probably haven't evendiscovered yet because maybe
potentially lack of research,lack of funding to actually go
out and discover these kinds ofthings, and I think you are that
kind of person that likes todiscover these types of new
things.
Speaker 2 (30:15):
I do.
That scientific curiosity thatwas born within me years ago
still is what drives me andinterests me, and it just takes
a simple Google search to youknow Google sponges and cancer
and or marine natural productsand cancer or marine natural
(30:35):
products, medical uses and youcan see the vast amounts of
research that have that havegone on, that are ongoing and
that will go on in the future,and that's that's a really
exciting.
You know in the future andthat's a really exciting you
know enmeshment, if you will,between my previous passion of
(30:55):
marine biology and now myhealthcare aspirations, and I
think marrying those twotogether is honestly like a
dream come true for me.
So I'm excited to be a part ofit.
Speaker 1 (31:06):
I'm excited you are a part of it.
I'm excited that you are a partof it.
I'm excited to hear more aboutthis.
I think it's exciting, to bevery honest, to understand what
you're doing.
It can help our currentgenerations and our future
generations.
I've loved to see cancer justeradicated, so potentially,
maybe there's a way of doingthat, because if it's just
instructions that are beinggiven in the cellular world that
(31:30):
is gone amiss, it's like avirus.
Right, we have viruses in code,so it's a miscode.
Maybe there is something therethat we can reverse and get past
cancer and move on to otherchallenges in the human world.
Before I let you go, Kyle, Ialways like to ask my guests
this, because now I like to bevery, very transparent with my
audience how do you feel andthis is the first time you've
(31:53):
been on the Follow the Brandpodcast as a guest and now
you've gone through, you knowthe entire interviewing process
how do you feel about this?
Speaker 2 (32:03):
I loved it.
I loved how it was aconversation.
It didn't feel like aninterrogation.
I loved how it was aconversation.
It didn't feel like aninterrogation, um, and it's, it
was just a natural, you know,and it's it gives.
It gave me the platform to saya lot of the things that I just
don't get to do professionally.
I don't get to, you know,expound on on my interests.
I don't get to expound on my myyou know my professional
(32:28):
history and and where I've comefrom, where I am now and what I
want to do in the future.
So I'm very appreciative ofthis platform that you've
graciously given me and I'mexcited for what's to come and
hopefully to get on here againin the future.
Speaker 1 (32:44):
I'd love to have you on, I'd love to see you in
person again One of the eventsdown here in South Florida.
This has been wonderful.
Do you have the audience?
How to contact you?
Are you you know?
Is it LinkedIn?
Is it email?
What's the best way?
Speaker 2 (32:56):
Yeah, linkedin would be would be the quickest and
most efficient way.
You know, kyle Roebuck, if you,if you search that and you and
you can match my my profilepicture, which will be shared by
Grant, then you can find me,connect with me and reach out
with any questions you have.
(33:17):
And I'd love to connect and tobuild that community even
further.
Speaker 1 (33:23):
Oh yeah, and remember he's not with the Sears and
Roebuck family, he has his ownfamily.
I wish he's not with the Searsand Roebuck family.
He has his own I wish.
Speaker 2 (33:29):
I'm sorry, Grant, but if I was with Sears and Roebuck
, I probably wouldn't bespeaking with you right now.
Speaker 1 (33:35):
We talked about that earlier.
That is fine, but you do have afamily business here in Florida
.
Was it Roebuck and RoebuckInsurance?
Speaker 2 (33:42):
Yes, Roebuck Insurance, Roebuck I-N-S dot com
.
Excellent For any of yourinsurance needs.
That's I'm.
I decided not to go intoinsurance, but the rest of the
family is.
So if you need insurance,definitely give them a call.
Speaker 1 (33:57):
Well, we'll definitely do that and I
encourage your entire audience,your entire family, to tune into
all the episodes of follow thebrand.
They can do so at the numberfive, that's five star.
Bdm, that's B for brand, d fordevelopment and for masterscom.
This has been wonderful, kyle.
Thank you so much for being onthe show.
Speaker 2 (34:15):
Thank you so much for having me Grant Hope to see you
soon, Absolutely.
Welcome everybody to the Follow Brand Podcast.
This is your host, grantMcGaugh.
We're going to keep it righthere in South Florida, in
Broward County, at MemorialHealthcare System.
Kyle Roebuck here Now.
I ran into this gentlemanthrough the HIMSS organization.
I'm a big HIMSS fan, programchair for HIMSS for a very long
(00:23):
time, and I found his story tobe intriguing and I've done a
lot of work in the cancer world.
And we got to talking.
He said hey, grant, I'm doing alot in genetics, I'm doing
precision medicine, I'm doingthings that help cancer
treatment get better, and I wantto tell my story.
And I went well, let's hearyour story then, kyle, let's
(00:47):
talk about this.
First, introduce yourself.
Speaker 2 (00:51):
Hi everyone.
My name is Kyle Roebuck.
I am a molecular pathologytechnologist with Memorial
Healthcare System and I got mystart in research, interestingly
enough, in marine biology.
So I tell people that I'm amarine biologist turned health
care professional.
So that's the short story andthe long story could be for
(01:12):
another day.
Speaker 1 (01:15):
Well, you are a Florida.
You're Florida born, I wouldsay.
I mean literally born in thesame system in which you work
with.
Now, was that planned?
Tell us a little bit about yourbackground.
Speaker 2 (01:28):
By no means was it planned.
On a rainy day in August in1991, I was born at Memorial
Regional Hospital.
Back then it was calledMemorial Hospital, so I'm a
South Florida native through andthrough, grew up in Pembroke
Pines, went to Florida StateUniversity in Tallahassee and
(01:54):
then from there I went and didmy master's, my graduate
research at Nova SoutheasternUniversity, which another full
circle moment is.
Now I'm also teaching there asan adjunct professor.
So you can say that full circlemoments have pervaded my life
through and through.
So I'm very excited about thosetwo.
Speaker 1 (02:09):
I see you're a professor now at NOVA, you're
doing some work at Miami Collegeand obviously you do a lot of
work.
I mean, what is driving yourpassion in this world?
Most people you just said it isrolled off your tongue when
you're talking about a medical,biological pathology.
I mean that's a lot.
That's a lot of letters there.
Tell us exactly what that is.
Speaker 2 (02:30):
Yeah.
So what we do nowadays inprecision medicine and
specifically in oncology, we'removing away from the typical
naming cancers and naming tumorsby the site of origin and we're
moving towards identifying themby mutational profiles and what
mutations are in that patient'stumor and finding, finding
(02:53):
targetable treatments, precisiontreatments that are actually
going after those, thosemutations themselves, instead of
just a broad spectrumchemotherapy that you've been
getting for, you know, decadesfor now, you know up until now.
So that's an interesting partof the field and how we're
developing new therapies, youknow over time, and we're also
(03:14):
targeting specific mutations inthe patient's tumor instead of
just treating everyone as a onesize fits all type of approach.
Speaker 1 (03:21):
I think that's important.
And what you just said as faras therapies, medications, I
mean just having cancer itselfand telling somebody they have
cancer is tough and then if youhave more of a generic approach,
you really don't know how thatmedication or that therapy or
that treatment is going tobehave.
You know for that particularindividual, so kind of trial and
(03:44):
error.
So when I hear what you'resaying you were going more of a
precise treatment path, thatmeans you're honing in and
taking out all the unknowns,trying to get into a known
element and try to get to abetter result.
Have you seen that to be thecase now that you're in this
field and you're seeing the endresults of a lot of these cases?
Speaker 2 (04:07):
Yeah, I mean you could have two different tumors
that are from the same site oforigin, aka the lung, the brain,
pancreas but the mutationalprofiles could be completely
different.
And so, in order to have thatpersonalized approach, you have
to do the biomarker testing andonce you have those biomarkers
(04:28):
profiled, you can find whicheligible therapies are available
for that patient.
And so it really is a highlypersonalized approach.
That is, it's producing sideeffects that you get with
traditional chemotherapies andeventually being more effective
than those therapies.
Speaker 1 (04:48):
This is important.
Now, when you say biomarkers,are you talking about the
individual's biomarker or isthat or something specific in
the patient that is indicativeof?
Speaker 2 (04:58):
disease or of progression of disease, things
along those lines.
But specifically in oncology wetalk about biomarkers, as what
are the drivers of tumor genesisor what's deriving the
(05:21):
formation of that tumor?
And those are the types ofmutations that you're trying to
target and trying to investigateto find out what would be the
most efficacious andadvantageous treatment to
basically combat thattumorigenesis or the formation
of that tumor.
And I'm talking specificallyfor solid tumors in cancer.
(05:42):
Generically speaking, tumors orcancer is divided up into two
groups.
The solid tumors in cancer.
Generically speaking, tumors orcancer is divided up into two
groups the solid tumors and theblood cancers, which are the
leukemias, the lymphomas, themyelomas.
Those are also targetable, butthat's a different realm in
terms of biomedical research andand testing and that sort.
Speaker 1 (06:04):
As a.
You're a pathologist.
I want to help my audienceunderstand.
You know there's a.
You know the cancer doctor andan oncologist.
You are the pathologist.
How do you work together?
Speaker 2 (06:20):
So I'm not a pathologist.
A pathologist is an MD, is atrained doctor.
So I'm a molecular pathologytechnologist and what I do is I
perform the testing.
I perform the testing from thetissue all the way up until
there's data that is informativefor the oncologist to use in
guiding their treatment, theirtreatment regimen.
(06:41):
So we work intimately with thepathologists, who in turn work
with the oncologists, which arethe actual treating physicians
that are dealing with patientsday in and day out.
So that's the main distinctionthere.
Speaker 1 (06:56):
That's a major distinction.
So we're like, when you go inand I've seen this happen you go
in, you get a biopsy, which isa piece of tissue, right, they
take that biopsy and then theytake it through different
testing.
So when they take it throughdifferent testing, is that your
world?
You're actually looking at thattissue and trying to figure out
what's going on.
Speaker 2 (07:15):
That's exactly right.
So normally a person has abiopsy or a surgery and a piece
of tissue is taken out of them,and traditionally it's fixed in
a chemical called formalin,which stabilizes it, what we
call histologically, which is itpreserves the molecular
structure of all of the internalcomponents of that tissue.
(07:36):
And then afterwards, after it'sfixed in that chemical, it's
embedded in what's calledparaffin, paraffin wax, and that
combination of the formalinfixation and the paraffin
embedding is what we call.
It is called FFPE.
That's what the FFPE stands forand that's traditionally what's
(07:56):
used nowadays to do thediagnostics.
And so that's essentially yourstarting tissue that you begin
the process of discovering thesebiomarkers.
Speaker 1 (08:07):
This is interesting.
Now I want to ask becauseyou're at this juncture
intersection of health care andtechnology because I met you at
HIMSS HIMSS is the HealthInformatics Systems Society.
Now I'm curious as to howyou're applying technology.
Are you're applying, you know,known AI algorithms?
(08:30):
Are you doing you know scanningimaging?
Tell us how you utilizetechnology in your trade.
Speaker 2 (08:35):
So one particular method to discover these
biomarkers is callednext-generation sequencing and
that's a method to scanessentially a vast majority of
biomarkers within a tumor.
In this, if we give thisexample in oncology, to find all
of the specific nucleotidebases that are in a sequence
(08:56):
that make up that tumor and Tofind those mutations, we have to
align those sequences to what'scalled a reference genome,
which is a grouping of humangenomes that have been kind of
the gold standard of what we useas comparison to basically call
mutations in that patient'stumor.
(09:17):
And so there's a lot oftechnological requirements to do
that, a lot of algorithms, alot of information technology
type solutions that are neededto do that computational
(09:38):
generation of that data.
So that's really the demand forinformation technology and use
(10:04):
of algorithms and importing thatdata into patient charts and
into EHRs.
Speaker 1 (10:10):
This is important information.
So you're taking massiveamounts of data, of information
that you have in variousdatabases to, I guess,
cross-reference, trying to getto a particular understanding of
what you have in front of youas far as this tissue, whatever
its molecular regeneration, isdoing to kind of isolate the
(10:34):
cancer and what it is.
A lot of people and I wouldlike you to tell our audience
what exactly is cancer.
I mean, they understand it's adifferent cellular generation,
but it's a type of disease thatis different from other things
(10:55):
that are happening that causesyou to do this kind of work.
Tell us more about what canceris and how, when you have all
this data and this information,what you're able to then
instruct the oncologist orpathologist on.
Speaker 2 (11:13):
So when you break it down into the simplest terms,
cancer is really justuncontrolled cellular division.
So normally in our normal cellsthey go through a series of
checkpoints as they get ready todivide and they grow and they
divide again under a processcalled mitosis.
In cancerous cells theinstructions to go through those
(11:38):
processes are a little bitdamaged and so the cells don't
normally go through or don't gothrough those processes checked
in a series of checkpoints.
They're bypassing thosecheckpoints, they're going
faster, they're multiplyingunregulated and unchecked and
that's what causes the eventualformation of a tumor, which is
(12:00):
just a bunch of cells growing inone area that form an actual
mass.
So that's really what cancer is.
It's uncontrolled cell divisionand cells that kind of have
gone rogue compared to the cellsthat are essentially behaving
normally.
Speaker 1 (12:16):
This is interesting, but we don't know what causes
that to happen.
What causes that mutation?
Is that what you say?
It's in the instructions at thecellular level.
Do we have information aboutthat?
One group is called oncogenesand then another group is called
tumor suppressor genes.
Speaker 2 (12:31):
So tumor suppressor genes are there and their main
responsibility is to inhibituncontrolled cell division.
And so in those tumorsuppressor genes, if those are
(12:53):
mutated, they are not doingtheir job to suppress tumor
formation.
And conversely, in oncogenes,those are genes that induce
cellular proliferation andcellular division.
So by the absence of mutationsin oncogenes and by the presence
(13:15):
of mutations in tumorsuppressor genes, the
combination of those or themworking by themselves, will lead
to the production of a tumor.
Speaker 1 (13:27):
And then do you take this information.
Once you've done your work andyou've done your research, then
you sit down with the oncologistor the pathologist.
This is the work that I'mpresenting to you.
Is that what happens, or is itdifferent?
Speaker 2 (13:43):
Yeah, so that data?
Is that what happens or is itdifferent?
Yeah, so that's that data is isprovided to a pathologist and
that data is analyzed by thatpathologist and they determine
what is relevant for that tumortype and so that once that data
report is completed, that getssent to the oncologist and then
that oncologist digests thatinformation with all the other
(14:05):
information that they're gettingand decides on a treatment
regimen from that data.
Speaker 1 (14:10):
This is interesting.
Now you said you're a professor, and you're a professor at two
institutions, at NOVA and alsoMiami Dade College.
Are you teaching this type ofinformation and technology and
and or is it something totallydifferent?
Speaker 2 (14:26):
I'm teaching this in a much more rudimentary sense,
um undergraduate and graduatelevel um, not specifically
cancer related, but um more of aa generic genomics and genome
biology sense Um, but the theprinciples and the ideas and the
concepts are similar.
It's just on a much moreundergraduate and graduate level
(14:50):
, not as high level as what I'mspeaking about now and what I do
on a day-to-day basis in thelab.
Speaker 1 (14:58):
Yes, exactly Now, genomics, genomics.
There's different distinctions,right as we get into now
genomics and genomics genomics.
There's different distinctions,right as we get into now
genomics and genomics is a wholenother animal because it
affects so many different things.
And how do you look at genomics?
And if you had to give adefinition like hey, professor
roebuck, what is genomics?
Speaker 2 (15:21):
well, it's really the study of a genome, of an
organism in its broadest sense,and that's where I came from
research actually on marineinvertebrates and organisms in
the ocean that are reallyrudimentary and preliminary
study organisms for things thatare happening in cancer and a
(15:47):
lot of, for example, a lot ofcancer drugs are isolates from
sponges or are derivatives ofsecondary metabolites of sponges
that are actually found in theocean.
So that was my my first workabout a decade ago, but then
it's led me here to to do thework on actual patients that
have been diagnosed with cancerand has offered me the ability
(16:08):
to give back so much more of myeducation and my background to
help human health in a muchgreater sense.
So that's kind of the journeyI've a little bit longer of a,
of an explanation of the journeyI've been on.
Speaker 1 (16:24):
No, this is interesting.
You just told me that you arecuring cancer from the ocean and
beings in the ocean.
Is that what I heard?
Speaker 2 (16:35):
Yes, yeah.
So most people, a lot of people, are surprised at the fact that
a lot of the cancer drugs, avast majority of the cancer
drugs, have been modeled or havebeen derived or have been
synthetically made based off ofderivatives of sponges and other
organisms in the ocean, andthat's, that's another, just
(16:56):
another reason why we need toprotect the oceans, but that's
another, another talk in and ofitself, another talk in and of
itself.
But, yeah, that's that's again.
That's that's part of my storyand how I've I've moved as a
move from a marine biologistturned to healthcare
professional.
Speaker 1 (17:13):
Now, as you go through that story, I want you
to think about this you know,starting out and getting your
undergrad and then going throughgrad school, now being out in
the world actually doing thiswork, teaching this work, what
is the most interesting thing?
That just really kind of mindblows you about the work that
(17:34):
you do?
Speaker 2 (17:36):
Really, I think it's just the fast-paced nature of
how many things are developingon a day-to-day basis, what
things are being discovered on aday-to-day basis, what things
are being discovered on aday-to-day basis.
That's what, that's what got meso interested in science in the
first place.
It's just how much technologyis changing, how much we're
finding out day-to-day newdevelopments, new, new
discoveries, and that's, to me,is the most exciting part of
(18:00):
science in general.
And then, even more so, biology, and if you get really granular
in terms of what I do today iscancer biology.
Speaker 1 (18:11):
You've intrigued me.
I mean I've learned somethingbig.
For me it's a big thing thatwe're getting cancer treatments
from microorganisms or organismsin the ocean that we find that
then can then combat thismutation and really your body is
kind of fighting itself is whatI'm hearing in cancer, and I've
(18:35):
heard that there's certainother causes.
People are looking at dietcould be a cause.
There's some external forcesthat could be getting in there
and creating these types ofthings.
Or maybe your immune system isjust not as strong to withstand
some of these activities thatare going on at the cellular
level.
I mean, this sounds to be tosolve for this problem that's
(19:09):
occurring within a person.
I find that fascinating.
Speaker 2 (19:15):
It is.
It really is fascinating aboutall of the biomedical research
that's going into cancer itselfand finding information about
all the factors that could gointo the production of a tumor
inside your body and what, what.
It also makes you appreciatehow many things have to go right
, because in the, in an instant,things can go wrong, and so it
(19:38):
really it.
It makes me, it reminds me, howmany things have to go right,
and and and.
It gives me a much greaterappreciation for science, for
biology, for what I've done inthe past, what I'm doing now,
and just the benefits that arebeing imparted onto human health
(20:00):
.
Speaker 1 (20:01):
Now you've been invited on many stages.
People want to hear from youand talk to you about your
research right and what you'redoing.
Why are you, kyle Roebuck,being asked to come onto these
stages and what exactly is thekind of knowledge that you're
imparting?
Speaker 2 (20:20):
I think it's my diverse background, the
different things that I've beenlucky enough to be a part of and
to experience and really learn.
I think that multidisciplinaryand that diverse background is a
huge attribute for myself andmy career and it's given me
(20:41):
perspective and it's allowed meto learn things that most other
people haven't learned, that aremaybe in the clinic and in
healthcare, because I've comefrom research and now I'm in the
clinic and I'm doing clinicalstuff.
So I think that that diversityand that multidisciplinary
background is is very beneficialfor my, for myself and my
(21:02):
career, and I think it's alsobecome beneficial to you know my
current role and at at you knowmy current day job, and then
also for my, my professor.
You know my, my, my, myteaching responsibilities as
well.
Speaker 1 (21:18):
I tell you you've sold me on your credibility and
your authenticity when you marrythose teams together that you
know you, when you say somethingin this realm it rings true.
People like huh, you know ifkyle?
I'm sure kyle knows what he'stalking about because he's done
the research.
You know you always like thathe's not going to just throw
(21:39):
some ideas out there.
Like you know, I've done theresearch, I've seen the trials.
I know what happens on thebefore, the during and the after
.
I want to ask you this In fiveyears, let's say we fast forward
five years it's the year 2030.
What is Kyle Roebuck doing?
Speaker 2 (22:02):
I think that's the exciting part is the not knowing
, because so much is changingand so much has changed in my
life in the last three and ahalf four years and I think that
that the industry that I'mworking in is is is
exponentially changing, dayafter day and year after year,
so I don't really know where mycareer is going to take me.
(22:23):
I'm just excited for the ride.
Speaker 1 (22:26):
Well, let's take that for a ride just a little bit
further.
I want to unpack that just alittle bit.
I want to ask you this If youcould make a difference in what
you're doing in cancer treatment, money wasn't an object.
Nothing was an obstacle in yourway.
Let's just say, what would thatbe?
Speaker 2 (22:53):
your way.
Let's just say, what would thatbe?
I think, in the most basicsense, I would just like to get
cancer patients treated fasterand whether it be you know
diagnosed faster.
We talk a lot about screeninginitiatives nowadays.
We talk about education, wetalk about advocacy.
All of those things will helpbring diagnostics of cancer up
(23:15):
to the forefront and expeditethose, so that you are not
diagnosing people in late stagecancer, You're not diagnosing
metastatic disease.
You can help save more livesbecause you're getting those
people in the appropriatetreatments faster and that, I
think, is is the most ambitiousand and and worthwhile goal that
(23:40):
we can, that we can go forright now and we can strive to,
to, to, you know, work towards.
Speaker 1 (23:46):
I like that.
I think that's a big, that'snot only a nice goal, that's
something we can change.
The awareness factor, like yousaid, screening, making sure
that we're informing ourpopulation, our communities.
You've got to get in thereearly and get these kinds of
(24:06):
screenings to take place.
You know, and so answer me this, because something you know you
get a yearly physical right,but cancer screen you don't
normally get screened for cancer.
How can we help with that?
Speaker 2 (24:22):
I think there's.
It depends on the specialty,the medical specialty, I think.
You know.
At my last physical I was asked, you know, when were you at
your dentist the last time?
When were you at adermatologist the last time?
Because of the prevalence,especially in South Florida, of
skin cancer and how things arego unnoticed or you don't.
(24:42):
You know, things are out ofsight, out of mind and, and you
know, going to those thoseprimary visit, the primary
doctor visits that are at, thosedoctors are asking you, are you
going to those specialties?
Are you having those regularcheckups?
Are you doing as much as youcan to preempt any of this?
you know, this possiblediagnosis of of cancer, whether
(25:05):
it be you know an optometrist,or you know a urologist or a you
know a gastroenterologist.
Are you having those symptoms?
Are you?
Are you, are you being providedthat education so that, when
you do potentially have thosesymptoms, are you aware how to
go about it?
What do you need to do and thatI think is really powerful, and
(25:28):
how?
How you know, I thinkhealthcare is changing, and and
to have to enable patients totake ownership of their own
healthcare and to be their bestadvocate and understand that you
know, your intuition may be theright call.
Even though you might bedismissed by by a doctor, you
know your body and you know yourhealth better than anyone else
(25:50):
does, and so enabling andempowering patients to take
ownership of their health care,I think, is another great
initiative that's going on rightnow.
Speaker 1 (26:00):
I think you're right.
I talked to a doctor lastsummer and he was a cancer
doctor, oncologist in themelanoma world, and we're
talking about melanoma and Ididn't know.
He said do you realize, likemost people, when they actually
get, uh, melanoma or you knowthe cancer, they get it when
(26:22):
they're a child, right in thesun, but it doesn't develop, you
know, until usually much later,so you're already exposed to it
.
You were you.
You don't even realize youcould have been five, six years
old, because I guess somethinglike your skin is not as strong
to withstand some of the sun'srays and that type of thing.
(26:44):
I didn't know that, you know.
I just had no idea that goingto the beach you're five, six
years old and if you didn't havethe right sunblocks on, you can
be developing cancer and youwouldn't even realize you have
it two years later.
Speaker 2 (27:00):
Right, and it could be.
Children don't like to listento their parents and if they to
being told, being told, go puton the sunblock and they don't
put it on well enough or theydon't do it at all, you know
that that could be another,another issue, um, but yeah,
it's a lot of a lot.
There's a lot of, um, potentialcauses of, of, of cancer, and I
think, especially in SouthFlorida, being the, you know,
(27:23):
the sunshine state and being ahotbed for no pun intended for
the sun, you know melanoma is aparticularly problematic, you
know, skin cancer type in theregion.
Speaker 1 (27:39):
So let me ask you this when it comes to genetics,
do you find that certaindemographics of people are prone
to different types of cancerswhether it's their ethnicity,
their race, maybe even theirlocation than others?
Speaker 2 (27:55):
I think there's a lot of research, especially now,
going into social determinantsof health and effects of race
and ethnicity and whetherthey're genetically predisposed
to different types of cancerbased on which demographic you
belong to.
But I think that's still anongoing area of research and it
(28:16):
needs a little bit moreinvestigation.
Speaker 1 (28:18):
Do you think?
Is it genetic?
Let's say your parent hadcancer?
Is the likelihood you hadcancer, or a grandparent, or is
it something different?
Speaker 2 (28:25):
or is it something different?
Yeah, I think there'sdefinitely anecdotal stories of
you know parents andgrandparents and family lineage
of whether it's breast cancer,colon cancer.
You know pancreatic prostate,what have you.
(28:46):
There's definitely anecdotalevidence that shows that there's
potentially a genetic linkthere.
And you know, we heard maybeabout a decade ago or 15 years
ago, you know, testing for theBRCA gene was a very popular
thing and so that's.
You know, there's some evidencethat there is a genetic
predisposition for developingcancer.
(29:07):
But I think it needs a lot moreinvestigational research to
really hammer down and nail downthat true, definite link.
Speaker 1 (29:17):
Well, I want to give you some research grants and
some more funding.
That sounds good.
Any way I can, because it'simportant, right.
It is Any way I can becauseit's important, right it is To
understand that I mean, whowould have known?
Hey, let's go out to the oceanand look at some sponges and do
some, you know, some research onthem and see what they have
(29:41):
going on with them, and then wecan actually help a human being
to cure cancer.
To me that's such a leap, it'salmost miraculous.
Like how would that even occur?
But you're telling me thatthere's so many things in the
natural world that potentiallycan help in our human journey
(30:01):
that we probably haven't evendiscovered yet because maybe
potentially lack of research,lack of funding to actually go
out and discover these kinds ofthings, and I think you are that
kind of person that likes todiscover these types of new
things.
Speaker 2 (30:15):
I do.
That scientific curiosity thatwas born within me years ago
still is what drives me andinterests me, and it just takes
a simple Google search to youknow Google sponges and cancer
and or marine natural productsand cancer or marine natural
(30:35):
products, medical uses and youcan see the vast amounts of
research that have that havegone on, that are ongoing and
that will go on in the future,and that's that's a really
exciting.
You know in the future andthat's a really exciting you
know enmeshment, if you will,between my previous passion of
(30:55):
marine biology and now myhealthcare aspirations, and I
think marrying those twotogether is honestly like a
dream come true for me.
So I'm excited to be a part ofit.
Speaker 1 (31:06):
I'm excited you are a part of it.
I'm excited that you are a partof it.
I'm excited to hear more aboutthis.
I think it's exciting, to bevery honest, to understand what
you're doing.
It can help our currentgenerations and our future
generations.
I've loved to see cancer justeradicated, so potentially,
maybe there's a way of doingthat, because if it's just
instructions that are beinggiven in the cellular world that
(31:30):
is gone amiss, it's like avirus.
Right, we have viruses in code,so it's a miscode.
Maybe there is something therethat we can reverse and get past
cancer and move on to otherchallenges in the human world.
Before I let you go, Kyle, Ialways like to ask my guests
this, because now I like to bevery, very transparent with my
audience how do you feel andthis is the first time you've
(31:53):
been on the Follow the Brandpodcast as a guest and now
you've gone through, you knowthe entire interviewing process
how do you feel about this?
Speaker 2 (32:03):
I loved it.
I loved how it was aconversation.
It didn't feel like aninterrogation.
I loved how it was aconversation.
It didn't feel like aninterrogation, um, and it's, it
was just a natural, you know,and it's it gives.
It gave me the platform to saya lot of the things that I just
don't get to do professionally.
I don't get to, you know,expound on on my interests.
I don't get to expound on my myyou know my professional
(32:28):
history and and where I've comefrom, where I am now and what I
want to do in the future.
So I'm very appreciative ofthis platform that you've
graciously given me and I'mexcited for what's to come and
hopefully to get on here againin the future.
Speaker 1 (32:44):
I'd love to have you on, I'd love to see you in
person again One of the eventsdown here in South Florida.
This has been wonderful.
Do you have the audience?
How to contact you?
Are you you know?
Is it LinkedIn?
Is it email?
What's the best way?
Speaker 2 (32:56):
Yeah, linkedin would be would be the quickest and
most efficient way.
You know, kyle Roebuck, if you,if you search that and you and
you can match my my profilepicture, which will be shared by
Grant, then you can find me,connect with me and reach out
with any questions you have.
(33:17):
And I'd love to connect and tobuild that community even
further.
Speaker 1 (33:23):
Oh yeah, and remember he's not with the Sears and
Roebuck family, he has his ownfamily.
I wish he's not with the Searsand Roebuck family.
He has his own I wish.
Speaker 2 (33:29):
I'm sorry, Grant, but if I was with Sears and Roebuck
, I probably wouldn't bespeaking with you right now.
Speaker 1 (33:35):
We talked about that earlier.
That is fine, but you do have afamily business here in Florida
.
Was it Roebuck and RoebuckInsurance?
Speaker 2 (33:42):
Yes, Roebuck Insurance, Roebuck I-N-S dot com
.
Excellent For any of yourinsurance needs.
That's I'm.
I decided not to go intoinsurance, but the rest of the
family is.
So if you need insurance,definitely give them a call.
Speaker 1 (33:57):
Well, we'll definitely do that and I
encourage your entire audience,your entire family, to tune into
all the episodes of follow thebrand.
They can do so at the numberfive, that's five star.
Bdm, that's B for brand, d fordevelopment and for masterscom.
This has been wonderful, kyle.
Thank you so much for being onthe show.
Speaker 2 (34:15):
Thank you so much for having me Grant Hope to see you
soon, Absolutely.
Popular Podcasts
24/7 News: The Latest
The latest news in 4 minutes updated every hour, every day.
Therapy Gecko
An unlicensed lizard psychologist travels the universe talking to strangers about absolutely nothing. TO CALL THE GECKO: follow me on https://www.twitch.tv/lyleforever to get a notification for when I am taking calls. I am usually live Mondays, Wednesdays, and Fridays but lately a lot of other times too. I am a gecko.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.